Global capital is shifting towards electronics and AI in Asia. India's foreign direct investment slowdown is not a major concern. Asia's ex...

Prices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Gurugram authorities uncovered a counterfeit Mounjaro operation. Police seized fake diabetes and weight loss injections valued at ₹70 lakh....

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

India’s pharmaceutical industry faces a potential raw material crunch after the government restricted surplus ammonia supply to fertiliser ...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

Ankit Gupta spoke to ET ahead of the accelerator’s Startup School event in Bengaluru on April 18 — the first in India. In order to tap aspi...

India's drug companies face a tough race in the global biologics market. China is quickly becoming a leader in biotech supply chains. India...

Indian firms Hetero Labs Limited, Cipla Ltd, Annora Pharma Private Limited and Natco Pharma won the bids conducted by the Chinese health mi...

Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This breakthrough si...

Shanghvi believes market watchers are underestimating the potential in China for India’s largest drugmaker.

China initiated protocols on Tuesday to recall fake rabies vaccines sold in other countries and regions amid the recent vaccine scandal.

The Indian bulk drug industry is in dire straits and their prospects appear bleak unless the government takes immediate steps to support th...

Indian drug makers see a significant business opportunity in the American regulator’s decision to step up vigilance on Chinese companies.

The country’s drug regulator has banned import of raw material from 10 Chinese drug companies for supplying products without having the man...

US Food and Drug Administration’s ban on seven API products of Ranbaxy may turn out to be a boon for the company’s Chinese peers, according...